ノボノルディスクファーマ（株） 中部ブロック

General information

http://bit.ly/NN-disclaimer

This page isn’t intended for US audiences.

This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome Facebook members to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. 

This page is not intended for discussions about products made by Novo Nordisk A/S. As such, postings or comments that contain product discussions may be removed.

Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: http://bit.ly/1ZHK7wS

You can do it by calling the office on the telephone number listed or by email.

For other customer complaints please contact us here: http://bit.ly/1QEImMq

Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industries. Therefore, comments that pertain to legal matters or regulatory issues may be removed. 

Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other Facebook users.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,